Immunic receives notice of allowance for composition-of-matter patent in the united states for imu-856, a small molecule modulator targeting restoration of intestinal barrier function and regeneration of bowel epithelium

New york , aug. 16, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company has received a notice of allowance from the u.s. patent and trademark office (uspto) for patent application 16/646130, entitled, "compound having cyclic structure." the patent covers composition-of-matter of imu-856 and related pharmaceutical compositions and is expected to provide protection into at least 2038, without accounting for potential patent term extension (pte).
IMUX Ratings Summary
IMUX Quant Ranking